NICE recommends thalidomide for patients with multiple myeloma

07/27/2011 | Bloomberg

U.K.'s National Institute for Health and Clinical Excellence has recommended the use of Celgene's thalidomide in combination with two other treatments as first-line treatment for patients with multiple myeloma who cannot tolerate high-dose chemotherapy and stem cell transplants. NICE said patients who cannot use thalidomide can use Velcade as an alternative drug.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA